Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.

DiCenzo R, Forrest A, Fischl MA, Collier A, Feinberg J, Ribaudo H, DiFrancecso R, Morse GD; AIDS Clinical Trials Group 388/733/5060 Study Team.

Antimicrob Agents Chemother. 2004 Mar;48(3):918-23.

2.

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

Shafer RW, Smeaton LM, Robbins GK, De Gruttola V, Snyder SW, D'Aquila RT, Johnson VA, Morse GD, Nokta MA, Martinez AI, Gripshover BM, Kaul P, Haubrich R, Swingle M, McCarty SD, Vella S, Hirsch MS, Merigan TC; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2304-15.

3.

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dubé MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC, Hirsch MS; AIDS Clinical Trials Group 384 Team.

N Engl J Med. 2003 Dec 11;349(24):2293-303.

4.

Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry.

Frerichs VA, DiFrancesco R, Morse GD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Apr 25;787(2):393-403.

PMID:
12650761
5.

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.

Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM.

Clin Pharmacol Ther. 2002 Jan;71(1):57-67.

PMID:
11823758
6.

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Smith PF, DiCenzo R, Morse GD.

Clin Pharmacokinet. 2001;40(12):893-905. Review.

PMID:
11735608
7.

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, Becker MI, Holland D, Connor JD, Luzuriaga K; Pediatric ACTG 356 Investigators.

Pediatr Infect Dis J. 2001 Aug;20(8):746-51.

PMID:
11734735
8.

Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.

Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA.

AIDS. 2001 May 25;15(8):991-8.

PMID:
11399981
9.

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.

Villani P, Regazzi MB, Castelli F, Viale P, Torti C, Seminari E, Maserati R.

Br J Clin Pharmacol. 1999 Nov;48(5):712-5.

10.

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Barry M, Mulcahy F, Merry C, Gibbons S, Back D.

Clin Pharmacokinet. 1999 Apr;36(4):289-304. Review.

PMID:
10320951
Items per page

Supplemental Content

Write to the Help Desk